Current trends in perioperative treatment of resectable gastric cancer  

作　　者：İbrahim Yıldız Leyla Özer Elif Şenocak Taşçı İbrahim Vedat Bayoglu Erman Aytac 

机构地区：[1]Department of Medical Oncology,Acıbadem MAA University,İstanbul 34567,Turkey [2]Department of Medical Oncology,Acıbadem University,İstanbul 34567,Turkey [3]Department of Medical Oncology,Marmara University,İstanbul 12345,Turkey [4]Department of Surgery,Acibadem University School of Medicine,Istanbul 34567,Turkey

出　　处：《World Journal of Gastrointestinal Surgery》2023年第3期323-337,共15页世界胃肠外科杂志（英文版）（电子版）

摘　　要：In the last few decades,the treatment strategy for locally advanced resectable gastric cancer(GC)has shifted to a multimodal approach,which potentially decreases recurrence risk and improves survival rates.Perioperative therapy leads to downstaging,increased curative resection rates,and prolonged disease-free and overall survival,by preventing micrometastases in patients with resectable GC.Application of neoadjuvant therapy provides information about tumor biology and in vivo sensitivity.A consensus regarding the therapeutic approach for non-metastatic GC does not exist,and many clinical trials aim to clarify this aspect.Advances in precision medicine and the role of immunotherapy have been the focus of research in GC treatment.Herein,the current status and possible future developments of perioperative therapy for locally advanced resectable GC are reviewed,based on the most recent randomized clinical trials.

关 键 词：Perioperative treatment IMMUNOTHERAPY NEOADJUVANT CHEMOTHERAPY Gastric cancer ADJUVANT 

分 类 号：R735.2[医药卫生—肿瘤]